However, there is increasing evidence that reduced levels of APPsα and loss of APP-mediated functions may contribute to cognitive dysfunction in AD and augmentation of α-secretase activity has been suggested as a therapeutic approach for AD [4,5]. The gene discussed is APP; the disease is Alzheimer disease.